Vikas Dandekar

A new policy for clinical trials may be unveiled next month

NPPA issues memorandum to monitor prices of 19 medical devices

In a latest crackdown to curb high prices of medical devices, NPPA or the National Pharmaceutical Pricing Authority, India's drugs pricing watchdog, has issued a memorandum to monitor prices of 19 medical devices sold.

Swadeshi Jagran Manch writes to PM Modi on drug prices

Swadeshi Jagran Manch, the economic outfit of RSS, has shot off a letter to Prime Minister Narendra Modi accusing that the department of pharmaceuticals (DoP) and the NITI Ayog are colluding with pharma companies to sabotage the drug price control regime.

Teva offers to buy out Mylan: What does it mean for Natco

Natco is engaged in a legal battle to launch a generic version of Teva's top-selling drug Copaxone, patent on which expires in September.

US Cong probe unusual, may add more drug players: PharmAsia

According to Vikas Dandekar, the scale of investigation by the US Congress is unprecedented and so 10 drugs and 14 generic companies as of now looks like a representative figure.

DRL-GSK generic formulations deal under review: PharmAsia

The DRL-GSK deal was to sell branded generic formulations in emerging markets and was entered into in 2009.

Sun's Halol audit may be a routine exercise: Expert

The US drug regulator is conducting audits at Sun Pharma's Halol facility in Gujarat. Sun had recalled multiple products made in this facility. Could this spell further trouble for Sun Pharma? Pharma Asia News India bureau chief Vikas Dandekar spoke with CNBC-TV18‘s Senthil Chengalvarayan and Sonia Shenoy to discuss the development.

'Doubt Ranbaxy claim that Mohali product filings not hit'

The question that needs to be resolved is what exactly is happening in terms of product filing and why is Ranbaxy saying that the product filings have not been impacted, says Vikas Dandekar, India Bureau Chief, PharmAsiaNews.Com.

Patients Or Patents?

By: Vikas Dandekar, PharmaAsia News

GoM vs pharma industry: Battling for market driven pricing

The pharma industry is on the edge of its seat with all eyes on the April 4 Group of Ministers (GoM) meeting which will decide on a final pricing policy for essential drugs, reports CNBC-TV18's Archana Shukla.

Biocon-Pfizer insulin deal might collapse soon: PharmAsia

The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.

Ranbaxy's ANDA transfer saw Teva launch Lipitor: PharmAsia

The deal between pharma majors Ranbaxy and Teva, for the sale of generic version of the blockbuster cholesterol drug – Lipitor left many in the industry surprised. Vikas Dandekar, Bureau Chief, PharmAsia News tells CNBC-TV18 that the contours of the deal revolved around three scenarios at best.

Cipla tells Merck your anti-AIDS drug too costly in India

Domestic pharma giant Cipla has taken the route of applying for a "voluntary license" for Merck's HIV Isentress (a generic raltegravir) saying it is not reaching needy patients in India and is prices exorbitantly.

Ranbaxy, Merck call off anti-infectives deal

Drug majors Ranbaxy and Merck have called off a deal that would have seen both the pharma giants join hands to research anti-infectives, reports PharmAsia News. The deal between the two companies was struck in 2008. Ranbaxy was to get milestones and an undisclosed upfront fee as part of the deal.